FTSV Forty Seven Inc.

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Latest News

1. 20 March 2020 Forty Seven, Inc. Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Business Highlights

   -- Presented Updated Data for Magrolimab Showing Robust, Durable Activity in MDS and AML ---- Presented Foundational Preclinical Data for FSI-174 and Entered into Collaborations with bluebird bio and Rocket

2. 11 March 2020 Forty Seven and Rocket Pharmaceuticals Announce Research Collaboration for Fanconi Anemia

   MENLO PARK, Calif. and NEW YORK, March 11, 2020 (GLOBE NEWSWIRE) -- Forty Seven, Inc. (NASDAQ:FTSV) and Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) announced today that they have entered into a research collaboration to

3. 02 March 2020 Gilead to Acquire Forty Seven for $4.9 Billion

   – Gilead Gains Forty Seven's Investigational Immuno-Oncology Therapy in Multiple Clinical Studies for Diseases Including Myelodysplastic Syndrome, Acute Myeloid Leukemia and Diffuse Large B-Cell Lymphoma – –

4. 25 February 2020 Forty Seven to Present at Upcoming Investor Conferences in March

   MENLO PARK, Calif., Feb. 25, 2020 (GLOBE NEWSWIRE) -- Forty Seven, Inc. (NASDAQ:FTSV), a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight against cancer,

5. 06 February 2020 Forty Seven to Present at Upcoming Investor Conferences in February

   MENLO PARK, Calif., Feb. 06, 2020 (GLOBE NEWSWIRE) -- Forty Seven, Inc. (NASDAQ:FTSV), a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight against cancer,

6. 10 January 2020 Forty Seven Announces 2020 Strategic Priorities and Expected Milestones

   -- Registration-Enabling Programs in MDS and DLBCL On-Track; Initiation of Phase 3 ENHANCE Trial in MDS and Phase 3 Trial in DLBCL Expected in 1Q and 2Q 2020 -- -- Updated Data from Ongoing Phase 1b Trial in Higher-Risk

7. 16 December 2019 Forty Seven, Inc. Announces Closing of Underwritten Public Offering and Exercise in Full of Option to Purchase Additional Shares

   MENLO PARK, Calif., Dec. 16, 2019 (GLOBE NEWSWIRE) -- Forty Seven, Inc. (NASDAQ:FTSV), a clinical stage immuno-oncology company, today announced the closing of its previously announced public offering of 5,589,000

8. 11 December 2019 Forty Seven, Inc. Prices Underwritten Public Offering of 4,860,000 Shares of Common Stock

   MENLO PARK, Calif., Dec. 11, 2019 (GLOBE NEWSWIRE) -- Forty Seven, Inc. (NASDAQ:FTSV), a clinical stage immuno-oncology company, today announced the pricing of its previously announced underwritten public offering of

9. 11 December 2019 Forty Seven, Inc. Announces Proposed Underwritten Public Offering of Common Stock

   MENLO PARK, Calif., Dec. 11, 2019 (GLOBE NEWSWIRE) -- Forty Seven, Inc. (NASDAQ:FTSV), a clinical stage immuno-oncology company, today announced that it has commenced an underwritten public offering of $140,000,000 of

10. 10 December 2019 Avadel Pharmaceuticals Appoints Dr. Mark McCamish to its Board of Directors

    DUBLIN, Ireland, Dec. 10, 2019 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating

11. 09 December 2019 Forty Seven, Inc. Announces Foundational Preclinical Data Supporting the Development of FSI-174 in Combination with Magrolimab as a Novel All Antibody Conditioning Regimen for Hematopoietic Stem Cell Transplantation

    -- Expect to Initiate Phase 1 Clinical Trial in Healthy Volunteers in First Quarter of 2020 ---- Forty Seven to Host Investor Event and Webcast at 8:00 p.m. ET -- MENLO PARK, Calif., Dec. 09, 2019 (GLOBE NEWSWIRE)

12. 09 December 2019 Forty Seven, Inc. Announces Updated Data from Ongoing Clinical Trial of Magrolimab Showing Robust, Durable Activity in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia

    -- CR Rate of 50% and ORR of 92% Observed in Untreated Patients with Higher-Risk MDS ---- CR/CRi Rate of 55% and ORR of 64% Observed in Patients with Untreated AML Who are Ineligible for Induction Chemotherapy ----

13. 12 November 2019 Forty Seven, Inc. Reports Third Quarter 2019 Financial Results and Recent Business Highlights

    -- On-Track to Initiate Potential Registration-Enabling Trials in MDS and DLBCL in 1Q 2020 ---- Entered into Collaboration with bluebird bio to Evaluate Antibody-Based Conditioning Regimen in Combination with LentiGlobin

14. 12 November 2019 bluebird bio and Forty Seven Announce a Research Collaboration to Study an All Antibody Conditioning Regimen for Use in Combination with Autologous Lentiviral Vector Hematopoietic Stem Cell Gene Therapy

    bluebird bio, Inc. (NASDAQ:BLUE) and Forty Seven, Inc. (NASDAQ:FTSV) announced today that they have entered into a research collaboration to pursue clinical proof-of-concept for Forty Seven's novel antibody-based

15. 06 November 2019 Forty Seven, Inc. to Present New Clinical and Preclinical Data on Magrolimab and FSI-174 at 61st ASH Annual Meeting

    MENLO PARK, Calif., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Forty Seven, Inc. (NASDAQ:FTSV), a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight against cancer,

16. 05 November 2019 Forty Seven Inc. to Report Third Quarter 2019 Financial Results on Tuesday, November 12, 2019

    MENLO PARK, Calif., Nov. 05, 2019 (GLOBE NEWSWIRE) -- Forty Seven Inc. (NASDAQ:FTSV), a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight against cancer, today

17. 27 September 2019 Forty Seven Inc. to Present at 2019 Cantor Global Healthcare Conference

    MENLO PARK, Calif., Sept. 27, 2019 (GLOBE NEWSWIRE) -- Forty Seven Inc. (NASDAQ:FTSV), a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight against cancer,

18. 03 September 2019 Forty Seven Inc. to Present at Morgan Stanley 17th Annual Global Healthcare Conference

    MENLO PARK, Calif., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Forty Seven Inc. (NASDAQ:FTSV), a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight against cancer,

19. 03 September 2019 Forty Seven, Inc. Granted Fast Track Designation for Magrolimab (5F9) for the Treatment of Myelodysplastic Syndrome and Acute Myeloid Leukemia

    MENLO PARK, Calif., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Forty Seven, Inc., a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight against cancer, today announced